Symbols / EDSA
EDSA Chart
About
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 12.61M |
| Enterprise Value | 9.85M | Income | -7.82M | Sales | — |
| Book/sh | 0.56 | Cash/sh | 1.44 | Dividend Yield | — |
| Payout | 0.00% | Employees | 17 | IPO | — |
| P/E | — | Forward P/E | -0.78 | PEG | — |
| P/S | — | P/B | 2.70 | P/C | — |
| EV/EBITDA | -1.19 | EV/Sales | — | Quick Ratio | 16.51 |
| Current Ratio | 16.82 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.07 | EPS next Y | -1.93 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-13 16:00 | ROA | -55.33% |
| ROE | -96.39% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 8.35M |
| Shs Float | 4.75M | Short Float | 0.39% | Short Ratio | 0.47 |
| Short Interest | — | 52W High | 2.95 | 52W Low | 0.72 |
| Beta | 0.21 | Avg Volume | 162.90K | Volume | 95.41M |
| Target Price | $11.00 | Recom | Strong_buy | Prev Close | $0.90 |
| Price | $1.51 | Change | 67.96% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.00
Mean price target
2. Current target
$1.51
Latest analyst target
3. DCF / Fair value
$-11.58
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.51
Low
$5.00
High
$19.00
Mean
$11.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-03 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-03-13 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
- Why Did EDSA Stock Rally More Than 70% Today? - Stocktwits ue, 24 Feb 2026 22
- Edesa drug cuts death risk to 24% in Phase 3 ARDS trial - Stock Titan ue, 24 Feb 2026 14
- Biotech Stock Edesa Biotech (Nasdaq:EDSA) Gains on News of Additional Positive Results from Phase 3 Paridiprubart Study - Investorideas.com ue, 24 Feb 2026 17
- Edesa Biotech stock surges on positive Phase 3 trial data - Investing.com ue, 24 Feb 2026 17
- 12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga ue, 24 Feb 2026 17
- Edesa Biotech Reports Positive Phase 3 Paridiprubart Results - TipRanks ue, 24 Feb 2026 15
- Favourable Signals For Edesa Biotech: Numerous Insiders Acquired Stock - simplywall.st Fri, 31 Oct 2025 07
- Edesa Biotech, Inc. Reports Q1 2026 Financial Results and Updates on Clinical Programs for EB06 and Paridiprubart - Quiver Quantitative Fri, 13 Feb 2026 08
- Edesa Biotech Inc. (EDSA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Sat, 14 Feb 2026 00
- Trading Recap: Is AMKR stock a value trap - Weekly Loss Report & Growth Focused Stock Reports - baoquankhu1.vn ue, 24 Feb 2026 06
- Edesa Biotech (Nasdaq: EDSA) widens loss as R&D spending climbs - Stock Titan Fri, 13 Feb 2026 21
- Edesa Biotech Reports Fiscal Year 2025 Financial Results and Updates on Clinical Programs | EDSA Stock News - Quiver Quantitative Fri, 12 Dec 2025 08
- EDSA’s Market Surge: Time to Jump In? - StocksToTrade ue, 28 Oct 2025 07
- EDSA Stock Price, News & Analysis - Stock Titan Fri, 25 Apr 2025 00
- symbol__ Stock Quote Price and Forecast - CNN Sat, 02 Mar 2024 03
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 11168 | — | — | Stock Award(Grant) at price 0.00 per share. | NIJHAWAN PARDEEP | Chief Executive Officer | — | 2026-02-02 00:00:00 | D |
| 1 | 10444 | — | — | Stock Award(Grant) at price 0.00 per share. | NIJHAWAN PARDEEP | Chief Executive Officer | — | 2026-01-05 00:00:00 | D |
| 2 | 8766 | — | — | Stock Award(Grant) at price 0.00 per share. | NIJHAWAN PARDEEP | Chief Executive Officer | — | 2025-12-01 00:00:00 | D |
| 3 | 6968 | — | — | Stock Award(Grant) at price 0.00 per share. | NIJHAWAN PARDEEP | Chief Executive Officer | — | 2025-11-03 00:00:00 | D |
| 4 | 5908 | — | — | Stock Award(Grant) at price 0.00 per share. | NIJHAWAN PARDEEP | Chief Executive Officer | — | 2025-10-02 00:00:00 | D |
| 5 | 5981 | — | — | Stock Award(Grant) at price 0.00 per share. | NIJHAWAN PARDEEP | Chief Executive Officer | — | 2025-09-11 00:00:00 | D |
| 6 | 6802 | — | — | Stock Award(Grant) at price 0.00 per share. | NIJHAWAN PARDEEP | Chief Executive Officer | — | 2025-08-01 00:00:00 | D |
| 7 | 7186 | — | — | Stock Award(Grant) at price 0.00 per share. | NIJHAWAN PARDEEP | Chief Executive Officer | — | 2025-07-02 00:00:00 | D |
| 8 | 270844 | — | — | Stock Award(Grant) at price 0.00 per share. | NIJHAWAN PARDEEP | Chief Executive Officer | — | 2025-06-02 00:00:00 | D |
| 9 | 11000 | — | — | Stock Award(Grant) at price 0.00 per share. | OLSON CHARLES V | Director | — | 2025-05-29 00:00:00 | D |
Financials
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -8.94K | -3.16K | -8.70K | -5.53K |
| TaxRateForCalcs | 0.15 | 0.15 | 0.40 | 0.26 |
| NormalizedEBITDA | -6.95M | -6.11M | -8.44M | -17.45M |
| TotalUnusualItems | -59.61K | -21.04K | -21.74K | -21.11K |
| TotalUnusualItemsExcludingGoodwill | -59.61K | -21.04K | -21.74K | -21.11K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -7.19M | -6.17M | -8.37M | -17.55M |
| ReconciledDepreciation | 119.27K | 186.05K | 183.47K | 118.19K |
| ReconciledCostOfRevenue | 0.00 | |||
| EBITDA | -7.01M | -6.13M | -8.46M | -17.47M |
| EBIT | -7.13M | -6.32M | -8.64M | -17.59M |
| NetInterestIncome | 2.56K | 153.50K | 289.85K | 63.52K |
| InterestIncome | 2.56K | 153.50K | 289.85K | 63.52K |
| NormalizedIncome | -7.13M | -6.15M | -8.36M | -17.53M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -7.19M | -6.17M | -8.37M | -17.55M |
| TotalExpenses | 7.13M | 6.32M | 8.64M | 17.59M |
| TotalOperatingIncomeAsReported | -7.91M | -7.01M | -9.22M | -18.37M |
| DilutedAverageShares | 5.68M | 3.20M | 2.86M | 2.38M |
| BasicAverageShares | 5.68M | 3.20M | 2.86M | 2.38M |
| DilutedEPS | -1.27 | -1.93 | -2.93 | -7.35 |
| BasicEPS | -1.27 | -1.93 | -2.93 | -7.35 |
| DilutedNIAvailtoComStockholders | -7.19M | -6.17M | -8.37M | -17.55M |
| NetIncomeCommonStockholders | -7.19M | -6.17M | -8.37M | -17.55M |
| NetIncome | -7.19M | -6.17M | -8.37M | -17.55M |
| NetIncomeIncludingNoncontrollingInterests | -7.19M | -6.17M | -8.37M | -17.55M |
| NetIncomeContinuousOperations | -7.19M | -6.17M | -8.37M | -17.55M |
| TaxProvision | 800.00 | 800.00 | 800.00 | 800.00 |
| PretaxIncome | -7.18M | -6.17M | -8.37M | -17.55M |
| OtherIncomeExpense | -59.61K | -6.28K | -21.74K | -21.11K |
| OtherNonOperatingIncomeExpenses | 14.77K | |||
| GainOnSaleOfSecurity | -59.61K | -21.04K | -21.74K | -21.11K |
| NetNonOperatingInterestIncomeExpense | 2.56K | 153.50K | 289.85K | 63.52K |
| InterestIncomeNonOperating | 2.56K | 153.50K | 289.85K | 63.52K |
| OperatingIncome | -7.13M | -6.32M | -8.64M | -17.59M |
| OperatingExpense | 7.13M | 6.32M | 8.64M | 17.59M |
| OtherOperatingExpenses | -783.89K | -698.28K | -581.04K | -780.26K |
| ResearchAndDevelopment | 3.67M | 2.88M | 4.79M | 13.34M |
| SellingGeneralAndAdministration | 4.24M | 4.13M | 4.43M | 5.04M |
| GeneralAndAdministrativeExpense | 4.24M | 4.13M | 4.43M | 5.04M |
| OtherGandA | 4.24M | 4.13M | 4.43M | 5.04M |
| GrossProfit | 0.00 | |||
| CostOfRevenue | 0.00 | |||
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| OrdinarySharesNumber | 7.14M | 3.25M | 3.08M | 2.38M |
| ShareIssued | 7.14M | 3.25M | 3.08M | 2.38M |
| TotalDebt | 0.00 | 19.87K | 94.49K | 18.98K |
| TangibleBookValue | 1.21M | -97.69K | 4.87M | 7.11M |
| InvestedCapital | 3.19M | 1.98M | 7.05M | 9.39M |
| WorkingCapital | 10.43M | -157.21K | 4.61M | 6.95M |
| NetTangibleAssets | 10.47M | -97.69K | 4.87M | 7.11M |
| CapitalLeaseObligations | 0.00 | 19.87K | 94.49K | 18.98K |
| CommonStockEquity | 3.19M | 1.98M | 7.05M | 9.39M |
| PreferredStockEquity | 9.26M | |||
| TotalCapitalization | 12.45M | 1.98M | 7.05M | 9.39M |
| TotalEquityGrossMinorityInterest | 12.45M | 1.98M | 7.05M | 9.39M |
| StockholdersEquity | 12.45M | 1.98M | 7.05M | 9.39M |
| OtherEquityInterest | -213.60K | -205.26K | ||
| GainsLossesNotAffectingRetainedEarnings | -165.77K | -242.61K | -214.65K | -213.60K |
| OtherEquityAdjustments | -165.77K | -242.61K | -214.65K | -213.60K |
| RetainedEarnings | -65.91M | -58.59M | -52.42M | -44.04M |
| AdditionalPaidInCapital | 14.75M | 13.58M | 13.04M | 11.18M |
| CapitalStock | 63.78M | 47.24M | 46.64M | 42.47M |
| CommonStock | 54.52M | 47.24M | 46.64M | 42.47M |
| PreferredStock | 9.26M | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 1.08M | 1.83M | 1.84M | 2.18M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 19.77K | 43.66K |
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| TradeandOtherPayablesNonCurrent | 0.00 | 43.66K | 47.20K | |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 19.77K | 0.00 | 20.51K |
| LongTermCapitalLeaseObligation | 0.00 | 19.77K | 0.00 | 20.51K |
| CurrentLiabilities | 1.08M | 1.83M | 1.82M | 2.14M |
| CurrentDebtAndCapitalLeaseObligation | 19.87K | 74.71K | 18.98K | 78.81K |
| CurrentCapitalLeaseObligation | 0.00 | 19.87K | 74.71K | 18.98K |
| PayablesAndAccruedExpenses | 1.08M | 1.81M | 1.75M | 2.12M |
| TotalAssets | 13.53M | 3.81M | 8.89M | 11.58M |
| TotalNonCurrentAssets | 2.02M | 2.14M | 2.45M | 2.48M |
| NonCurrentPrepaidAssets | 39.97K | 41.15K | 173.49K | 171.46K |
| GoodwillAndOtherIntangibleAssets | 1.98M | 2.08M | 2.18M | 2.28M |
| OtherIntangibleAssets | 1.98M | 2.08M | 2.18M | 2.28M |
| NetPPE | 0.00 | 18.36K | 100.08K | 31.16K |
| AccumulatedDepreciation | -52.55K | -43.85K | -39.52K | -33.85K |
| GrossPPE | 0.00 | 18.36K | 143.92K | 70.68K |
| OtherProperties | 18.36K | 91.37K | 18.46K | 96.57K |
| MachineryFurnitureEquipment | 52.55K | 52.55K | 52.21K | 48.84K |
| BuildingsAndImprovements | 18.46K | 96.57K | ||
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 11.51M | 1.68M | 6.44M | 9.09M |
| OtherCurrentAssets | 77.84K | 367.39K | 448.91K | 745.54K |
| PrepaidAssets | 745.54K | 948.64K | ||
| Receivables | 642.87K | 270.91K | 626.54K | 1.26M |
| AccountsReceivable | 642.87K | 270.91K | 626.54K | 1.26M |
| CashCashEquivalentsAndShortTermInvestments | 10.79M | 1.04M | 5.36M | 7.09M |
| CashAndCashEquivalents | 10.79M | 1.04M | 5.36M | 7.09M |
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| FreeCashFlow | -7.32M | -4.89M | -6.64M | -12.28M |
| RepaymentOfDebt | 0.00 | -29.53K | 0.00 | |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 17.60M | 729.39K | 4.35M | 11.96M |
| CapitalExpenditure | -5.66K | -6.15K | ||
| EndCashPosition | 10.79M | 1.04M | 5.36M | 7.09M |
| BeginningCashPosition | 1.04M | 5.36M | 7.09M | 7.84M |
| EffectOfExchangeRateChanges | 46.22K | -25.90K | 76.85K | -93.01K |
| ChangesInCash | 9.71M | -4.30M | -1.81M | -655.33K |
| FinancingCashFlow | 17.03M | 592.03K | 4.83M | 11.63M |
| CashFlowFromContinuingFinancingActivities | 17.03M | 592.03K | 4.83M | 11.63M |
| NetOtherFinancingCharges | -544.11K | -107.82K | -285.44K | -328.06K |
| ProceedsFromStockOptionExercised | -23.45K | 0.00 | 770.53K | 0.00 |
| NetPreferredStockIssuance | 9.88M | 0.00 | ||
| PreferredStockIssuance | 9.88M | 0.00 | ||
| NetCommonStockIssuance | 7.72M | 729.39K | 4.35M | 11.96M |
| CommonStockIssuance | 7.72M | 729.39K | 4.35M | 11.96M |
| NetIssuancePaymentsOfDebt | 0.00 | -29.53K | 0.00 | 0.00 |
| NetShortTermDebtIssuance | 0.00 | -29.53K | ||
| ShortTermDebtPayments | 0.00 | -29.53K | ||
| NetLongTermDebtIssuance | -29.53K | 0.00 | 0.00 | |
| LongTermDebtPayments | -29.53K | 0.00 | ||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | 0.00 | -5.66K | -6.15K | |
| CashFlowFromContinuingInvestingActivities | 0.00 | -5.66K | -6.15K | |
| NetInvestmentPurchaseAndSale | 0.00 | |||
| SaleOfInvestment | 0.00 | |||
| PurchaseOfInvestment | 0.00 | |||
| NetIntangiblesPurchaseAndSale | 0.00 | |||
| PurchaseOfIntangibles | 0.00 | |||
| NetPPEPurchaseAndSale | 0.00 | -5.66K | -6.15K | |
| SaleOfPPE | 0.00 | |||
| PurchaseOfPPE | 0.00 | -5.66K | -6.15K | |
| OperatingCashFlow | -7.32M | -4.89M | -6.64M | -12.28M |
| CashFlowFromContinuingOperatingActivities | -7.32M | -4.89M | -6.64M | -12.28M |
| ChangeInWorkingCapital | -985.65K | 571.07K | 308.00K | 2.89M |
| ChangeInPayablesAndAccruedExpense | -715.50K | 17.59K | -556.27K | 882.84K |
| ChangeInPrepaidAssets | 107.83K | 197.14K | 301.50K | -19.50K |
| ChangeInReceivables | -377.99K | 356.34K | 562.77K | 2.03M |
| OtherNonCashItems | -14.77K | |||
| StockBasedCompensation | 729.64K | 537.49K | 1.25M | 2.26M |
| DepreciationAmortizationDepletion | 119.27K | 186.05K | 183.47K | 118.19K |
| DepreciationAndAmortization | 119.27K | 186.05K | 183.47K | 118.19K |
| NetIncomeFromContinuingOperations | -7.19M | -6.17M | -8.37M | -17.55M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for EDSA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|